Cefadroxil
Cefadroxil (cefadroxil) is a small molecule pharmaceutical. Cefadroxil was first approved as Cefadroxil on 1982-01-01. It is used to treat bacterial infections, escherichia coli infections, impetigo, klebsiella infections, and pharyngitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Combinations
Cefadroxil (discontinued: Cefadroxil, Duricef, Ultracef)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefadroxil
+
Cefadroxil hemihydrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DURICEF | Warner Chilcott | N-050512 DISCN | 1982-01-01 | 2 products |
| DURICEF | Warner Chilcott | N-050527 DISCN | 1982-01-01 | 3 products, RLD |
| DURICEF | Warner Chilcott | N-050528 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefadroxil | ANDA | 2024-10-16 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | 2 | 1 | 2 | 5 |
| Communicable diseases | D003141 | — | — | — | — | 2 | 1 | 1 | 4 |
| Bacterial infections | D001424 | — | A49 | — | — | 1 | 1 | — | 2 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | 1 | 1 | — | 2 |
| Breast implantation | D019928 | — | — | — | — | — | 1 | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | 1 | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | — | 1 | — | — | 1 |
| Infectious skin diseases | D012874 | — | — | — | — | 1 | — | — | 1 |
| Bacterial skin diseases | D017192 | — | — | — | — | 1 | — | — | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | — | 1 |
| Exanthema | D005076 | HP_0000988 | — | — | 1 | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | — | 1 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | — | 1 |
| Anaphylaxis | D000707 | — | T88.6 | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | — | — | — | 1 |
| Drug hypersensitivity | D004342 | EFO_0009482 | T88.7 | — | 1 | — | — | — | 1 |
| Cephalosporin resistance | D018550 | — | Z16.19 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | 1 | — | — | — | — | 1 |
| Pyomyositis | D052880 | EFO_1001409 | M60.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | — | — | 2 | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 1 | 1 |
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | — | — | — | 1 | 1 |
| Pharyngitis | D010612 | — | R07.0 | — | — | — | — | 1 | 1 |
| Surgical wound infection | D013530 | — | — | — | — | — | — | 1 | 1 |
| Mammaplasty | D016462 | — | — | — | — | — | — | 1 | 1 |
| Mastitis | D008413 | EFO_1001034 | N61 | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefadroxil |
| INN | cefadroxil |
| Description | Cefadroxil monohydrate is the hydrate that is the monohydrate of the cephalosporin cefadroxil. It contains a cefadroxil. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1 |
Identifiers
| PDB | — |
| CAS-ID | 50370-12-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1644 |
| ChEBI ID | 3479 |
| PubChem CID | 47964 |
| DrugBank | DB01140 |
| UNII ID | Q525PA8JJB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cefadroxil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,945 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
666 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use